Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E

Climacteric ◽  
2009 ◽  
Vol 12 (4) ◽  
pp. 310-318 ◽  
Author(s):  
N. Biglia ◽  
P. Sgandurra ◽  
E. Peano ◽  
D. Marenco ◽  
G. Moggio ◽  
...  
2013 ◽  
Vol 21 (5) ◽  
pp. 1461-1474 ◽  
Author(s):  
Sylvain L’Espérance ◽  
◽  
Suzanne Frenette ◽  
Anne Dionne ◽  
Jean-Yves Dionne

2021 ◽  
Author(s):  
Beverley de Valois ◽  
Teresa Elaine Young ◽  
Pam Thorpe ◽  
Tarsem Degun ◽  
Karen Corbishley

Abstract PurposeWhile clinical trials provide valuable data about efficacy of interventions, findings often do not translate into clinical settings. We report real world clinical outcomes of a 15-year service offering breast cancer survivors auricular acupuncture to manage hot flushes and night sweats (HFNS) associated with adjuvant hormonal treatments. This service evaluation aims to 1) assess whether usual practice alleviates symptoms in a clinically meaningful way and 2) compare these results with scientific evidence. MethodsData were analysed from 415 referrals to a service offering women eight standardised treatments using the National Acupuncture Detoxification Association (NADA) protocol. Outcome measures administered at baseline, end of treatment (EOT), and four- and 18- weeks after EOT included Hot Flush Diaries, Hot Flush Rating Scale (HFRS) and Women’s Health Questionnaire (WHQ).Results2285 treatments were given to 300 women; 275 (92.3%) completed all eight treatments. Median daily frequency of HFNS reduced from 9.6 (IQR 7.3) to 5.7 (IQR 5.8) at EOT and 6.3 (IQR 6.5) 18 weeks after EOT. HFRS problem rating showed a clinically meaningful reduction of ≥2 points at all measurement points. WHQ showed improvements in several symptoms associated with the menopause. Two adverse events were reported, neither were serious. Results are comparable to published research.ConclusionThis first analysis of a long-term auricular acupuncture service compares favourably with outcomes of other studies for reducing HFNS frequency and associated menopausal symptoms. In day-to-day clinical practice, NADA appears to be a safe effective intervention for breast cancer survivors.


Climacteric ◽  
2011 ◽  
Vol 14 (1) ◽  
pp. 171-180 ◽  
Author(s):  
K. L. Rand ◽  
J. L. Otte ◽  
D. Flockhart ◽  
D. Hayes ◽  
A. M. Storniolo ◽  
...  

Breast Cancer ◽  
2015 ◽  
Vol 23 (2) ◽  
pp. 178-182 ◽  
Author(s):  
Iwona Wiśniewska ◽  
Bożena Jochymek ◽  
Monika Lenart-Lipińska ◽  
Mariusz Chabowski

2016 ◽  
Vol 27 (1) ◽  
pp. e12484 ◽  
Author(s):  
N. Biglia ◽  
V.E. Bounous ◽  
T. Susini ◽  
S. Pecchio ◽  
L.G. Sgro ◽  
...  

Maturitas ◽  
2009 ◽  
Vol 63 ◽  
pp. S34 ◽  
Author(s):  
N. Biglia ◽  
P. Sgandurra ◽  
E. Peano ◽  
G. Moggio ◽  
M. Spatola ◽  
...  

1998 ◽  
Vol 16 (2) ◽  
pp. 495-500 ◽  
Author(s):  
D L Barton ◽  
C L Loprinzi ◽  
S K Quella ◽  
J A Sloan ◽  
M H Veeder ◽  
...  

PURPOSE Hot flashes represent a substantial clinical problem for some breast cancer survivors. Although estrogen or progesterone preparations can alleviate these symptoms in many patients, concern remains regarding the use of hormonal preparations in such women. Thus, there is a perceived need for nonhormonal treatments for hot flashes for breast cancer survivors. Based on anecdotal evidence that vitamin E was helpful, we designed a trial to investigate this matter. METHODS We developed and conducted a placebo-controlled, randomized, crossover trial where, after a 1 week baseline period, patients received 4 weeks of vitamin E 800 IU daily, then 4 weeks of an identical-appearing placebo, or vice versa. Diaries were used to measure potential toxicities and hot flashes during the baseline week and the two subsequent 4-week treatment periods. RESULTS The 120 patients evaluated for toxicity failed to show any. The 105 patients who finished the first treatment period showed a similar reduction in hot flash frequencies (25% v 22%; P = .90) for the two study arms. A crossover analysis, however, showed that vitamin E was associated with a minimal decrease in hot flashes (one less hot flash per day than was seen with a placebo) (P < or = .05). At the study end, patients did not prefer vitamin E over the placebo (32% v 29%, respectively). CONCLUSION Although this trial was able to show a statistically significant hot flash reduction with vitamin E compared to a placebo, the clinical magnitude of this reduction was marginal.


Sign in / Sign up

Export Citation Format

Share Document